The new era of Pompe disease: Advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management
Authors:
- Priya S. KishnaniPKPriya S. Kishnani
- Nancy J. MendelsohnNMNancy J. Mendelsohn
- 17 January 2012
- journal article
- other
- Published by Wiley in American Journal of Medical Genetics Part C: Seminars in Medical Genetics
- Vol. 160C (1) , 1-7
Abstract
Pompe disease is an autosomal recessive neuromuscular disorder marked by progressive muscle weakness due to lysosomal buildup of glycogen. Presentation is described as a spectrum, varying by age of onset, organ involvement, and degree of myopathy. Given the phenotypic variability, Pompe disease is broadly classified into an infantile form and a late onset (juvenile, childhood, adult onset) form. Prior to the advent of enzyme replacement therapy (ERT) with alglucosidase alfa and approval for human use in 2006, the natural history was limited due to death before age 2 years for infantile onset cases and significant morbidity and early mortality for late onset Pompe disease (LOPD). ERT with alglucosidase alfa redefined the once fatal outcome in infantile Pompe, establishing an emergent phenotype. Treatment in late onset patients resulted in improved outcomes, enhancing understanding of the phenotype, presentation, and extent of organ involvement. This Issue of the Seminars seeks to enumerate the recent advancements in the field of Pompe disease, including newborn screening, novel therapeutic targets, new insights in the pathophysiology including role of autophagy, and impacts of long‐term disease burden and CNS glycogen accumulation on cognition in infantile survivors. It also addresses immunological challenges and the critical role of immunomodulation in ERT treatment outcome. Other topics discussed include the role of biomarkers in monitoring disease progression and treatment responses, the role of genotype in defining phenotype and treatment response, better insights into the clinical presentations in LOPD and finally the importance of a multidisciplinary approach to care with the role of physical therapy as an example. Many gaps in our scientific understanding of this disease still remain; however, we hope the next decade will bring new knowledge and therapies to the horizon.Keywords
This publication has 30 references indexed in Scilit:
- β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe diseaseMolecular Genetics and Metabolism, 2012
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe diseaseGenetics in Medicine, 2011
- Expanding the clinical spectrum of late-onset Pompe disease: Dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncoveredMolecular Genetics and Metabolism, 2011
- Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscleMolecular Genetics and Metabolism, 2011
- Hearing loss in Pompe disease revisited: results from a study of 24 childrenJournal of Inherited Metabolic Disease, 2010
- Immunomodulatory Gene Therapy Prevents Antibody Formation and Lethal Hypersensitivity Reactions in Murine Pompe DiseaseMolecular Therapy, 2010
- Oropharyngeal Dysphagia in Infants and Children with Infantile Pompe DiseaseDysphagia, 2009
- Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe diseaseNeurology, 2008
- Pompe disease diagnosis and management guidelineGenetics in Medicine, 2006
- Carbohydrate-remodelled acid α-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe miceBiochemical Journal, 2005